Glenmark Pharmaceuticals Limited (BSE:532296) has entered into a license agreement to acquire OmniAb, Inc. on January 11, 2018. As a part of the transaction, Glenmark Pharmaceuticals will be able to use the full OmniAb platform including OmniChicken, OmniRat, OmniMouse and OmniFlic to discover fully human mono- and multispecific antibodies. Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody.

Glenmark will be responsible for all costs related to the programs.